All opportunities
Internal Opportunity
Fractional Executive / Executive Advisory (Indicative 0.4 – 0.5 FTE / 16–20 Hours Weekly)
Remote / Hybrid Executive Model (Remote Executive Execution with Periodic On-Site Alignment)
Vice President Level
Medical Devices, Electromechanical Capital Equipment & Renal Care Technology

Vice President, Global Regulatory Affairs & Quality Assurance (Fractional / Executive Advisory Mandate)

Employer
Outset Medical, Inc. (NASDAQ: OM)
Industry
Medical Devices, Electromechanical Capital Equipment & Renal Care Technology
Location
San Jose, California, United States
Country
United States
Work arrangement
Remote / Hybrid Executive Model (Remote Executive Execution with Periodic On-Site Alignment)
Employment type
Fractional Executive / Executive Advisory (Indicative 0.4 – 0.5 FTE / 16–20 Hours Weekly)
Seniority
Vice President Level
Department
Global Regulatory Affairs, Quality Assurance & Clinical Compliance
Compensation
USD 162,000 – 216,000 per Year
Application status
Accepting applications
Closing date
2026-11-25
Closes in–d –h –m –s· Wednesday, 25 November 2026 at 16:19 (UTC)

Your application is received by Westbridge for review. We do not automatically forward materials to an employer.

About the role

The Vice President, Global Regulatory Affairs & Quality Assurance (Fractional Executive Mandate) is a senior strategic leadership appointment designed to provide executive-level regulatory foresight, enterprise quality governance, and commercialisation acceleration for complex, connected medical device platforms. Operating alongside the executive leadership team, this leader directs global regulatory strategy, FDA pre-market and post-market compliance, international market expansion pathways, and end-to-end Quality Management System (QMS) maturity. As Outset Medical scales its commercial footprint across acute care, outpatient clinics, and home dialysis settings, regulatory and quality execution serves as a primary driver of enterprise valuation, gross margin protection, and hospital system adoption. The incoming executive addresses critical operational inflection points, including next-generation hardware and software clearance pathways (510(k), De Novo, EU MDR), software as a medical device (SaMD) and cloud telemetry compliance, supplier quality resilience, and inspection readiness across global manufacturing and distribution operations. With functional authority over regulatory submission architecture, design control governance, and post-market surveillance frameworks, this executive bridges engineering innovation with rigorous clinical and regulatory standards. The long-term impact of the role lies in establishing a scalable, predictable regulatory and quality operating model that reduces time-to-market for product enhancements, eliminates compliance bottlenecks, and reinforces institutional trust among hospital networks, clinical partners, and global regulatory authorities.

Company overview

Outset Medical, Inc. (NASDAQ: OM) is a commercial-stage medical technology company pioneering first-of-its-kind technology designed to reduce the cost and complexity of dialysis. Headquartered in San Jose, California, the organisation designs, manufactures, and commercialises the Tablo® Hemodialysis System—an all-in-one, enterprise-grade dialysis console featuring integrated water purification, on-demand dialysate production, automated disinfection, and two-way wireless data connectivity. Outset Medical operates at the intersection of capital medical equipment, single-use consumables, and cloud-based digital health infrastructure. Its core business model combines console placements with recurring revenue from proprietary treatment cartridges and service contracts across acute hospital systems, sub-acute facilities, and home hemodialysis patients.

Key responsibilities

Enterprise Regulatory Strategy & Global Submission Architecture: Define and execute multi-year regulatory pathways for hardware iterations, single-use consumables, and connected software features across FDA (510(k), IDE, PMA/De Novo where applicable) and international jurisdictions (EU MDR, UKCA, Health Canada, APAC), directly accelerating commercial launch timelines.

Quality Management System (QMS) Governance & Inspection Readiness: Lead enterprise compliance with FDA 21 CFR Part 820 (QMSR alignment), ISO 13485, and MDSAP standards, maintaining continuous audit readiness for unannounced FDA inspections and Notified Body assessments.

Design Controls & Risk Management Oversight: Govern end-to-end design control frameworks and ISO 14971 risk management files from concept feasibility through design transfer, ensuring engineering velocity is balanced with rigorous verification, validation, and human factors engineering.

Software, Cybersecurity & Connected Health Compliance: Direct regulatory and quality protocols for embedded firmware, cloud telemetry, and data analytics platforms in alignment with FDA Premarket Cybersecurity guidance, IEC 62304, and HIPAA/GDPR privacy frameworks.

Supplier Quality Engineering & Supply Chain Resilience: Oversee supplier qualification, critical component audits, and contract manufacturer quality agreements to safeguard product reliability, prevent supply disruptions, and support gross margin improvement initiatives.

Post-Market Surveillance, CAPA & Field Action Governance: Direct complaint handling, Medical Device Reporting (MDR), vigilance reporting, root-cause investigations, and Corrective and Preventive Action (CAPA) effectiveness to protect patient safety and brand reputation.

Clinical Evaluation & Real-World Evidence Alignment: Partner with Clinical and Medical Affairs leadership to align clinical study protocols, Clinical Evaluation Reports (CERs), and Post-Market Clinical Follow-Up (PMCF) plans with evolving regulatory evidentiary standards.

Executive & Board Advisory Representation: Serve as a senior regulatory and quality advisor to the CEO, COO, and Board Quality & Compliance Committee, translating complex regulatory developments into actionable commercial and capital allocation recommendations.

Organisational Capability Building & Talent Mentorship: Mentor and elevate internal Regulatory Affairs and Quality Assurance directors and managers, establishing clear decision rights, streamlined SOPs, and a culture of proactive quality ownership across engineering and manufacturing teams.

Candidate profile

Minimum of 12-15+ years of progressive leadership experience within the medical device industry, including prior service at the Vice President or Senior Director level overseeing both Regulatory Affairs and Quality Assurance. Deep, hands-on expertise in FDA Class II/III medical devices, electromechanical capital equipment, single-use disposables, design controls (21 CFR 820.30), risk management (ISO 14971), and ISO 13485 QMS architecture. Demonstrated track record leading successful FDA 510(k) submissions, pre-submission (Q-Sub) negotiations, and FDA inspection management without critical unresolved observations. Proven ability to operate effectively in a high-impact executive advisory, consulting, or fractional leadership capacity alongside established C-suite teams. Comprehensive command of FDA QMSR / 21 CFR Part 820, ISO 13485:2016, ISO 14971 risk management, IEC 60601 electromechanical safety standards, IEC 62304 medical device software lifecycle processes, and FDA premarket cybersecurity guidance. Proficiency in clinical evaluation alignment (CER/PMCF), biocompatibility (ISO 10993), sterilisation validation, and hospital/home-use human factors engineering (IEC 62366). Essential: Bachelor's degree in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Life Sciences, or a related technical discipline. Executive Competencies: Strategic Regulatory Foresight; Executive Communication & Board Presence; Pragmatic Engineering Judgement; Cross-Functional Influence & Resilience.

Required qualifications

Minimum of 12-15+ years of progressive leadership experience within the medical device industry, including prior service at the Vice President or Senior Director level overseeing both Regulatory Affairs and Quality Assurance. Deep, hands-on expertise in FDA Class II/III medical devices, electromechanical capital equipment, single-use disposables, design controls (21 CFR 820.30), risk management (ISO 14971), and ISO 13485 QMS architecture. Demonstrated track record leading successful FDA 510(k) submissions, pre-submission (Q-Sub) negotiations, and FDA inspection management without critical unresolved observations. Proven ability to operate effectively in a high-impact executive advisory, consulting, or fractional leadership capacity alongside established C-suite teams. Comprehensive command of FDA QMSR / 21 CFR Part 820, ISO 13485:2016, ISO 14971 risk management, IEC 60601 electromechanical safety standards, IEC 62304 medical device software lifecycle processes, and FDA premarket cybersecurity guidance. Proficiency in clinical evaluation alignment (CER/PMCF), biocompatibility (ISO 10993), sterilisation validation, and hospital/home-use human factors engineering (IEC 62366). Essential: Bachelor's degree in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Life Sciences, or a related technical discipline.

Preferred qualifications

Prior leadership or senior functional experience within high-growth, commercial-stage medical technology innovators as well as Tier-1 multinational device manufacturers (e.g., surgical robotics, renal care, infusion systems, or connected diagnostic platforms). Direct international regulatory experience navigating EU MDR conformity assessments, MDSAP audits, Health Canada licensing, and APAC market registrations. Preferred: Master's degree in Biomedical Engineering, Regulatory Science, or Business Administration (MBA); Regulatory Affairs Certification (RAC) or ASQ quality engineering/auditing credentials.

Compensation & benefits

Salary: USD 162,000 – 216,000 per Year

Indicative Fractional Retainer: $13,500 – $18,000 USD per month ($162,000 – $216,000 USD annualized cash retainer), calibrated against a full-time Bay Area MedTech VP RA/QA base salary benchmark of $385,000 – $440,000 USD. Performance & Long-Term Incentives: Indicative milestone-based annual bonus target of 20%–30% of annualized retainer tied to major regulatory clearances and inspection outcomes, alongside potential advisory stock options or RSUs (subject to Board and compensation committee approval). Benefits & Expense Reimbursement: As a fractional executive engagement, standard W-2 healthcare/retirement benefits are replaced by the premium retainer and equity structure; approved business travel and regulatory representation expenses are reimbursed per corporate policy. All compensation figures represent indicative market-calibrated estimates and do not constitute a confirmed employment offer.

Work arrangements

Arrangement: Remote / Hybrid Executive Model (Remote Executive Execution with Periodic On-Site Alignment)

Location: San Jose, California, United States

Location: San Jose, California, United States. Work Model: Remote Executive Execution with Periodic On-Site Alignment (Remote / Hybrid Executive Model). Travel Requirements: Approximately 15%–20% domestic and selective international travel for agency meetings, supplier audits, and quarterly executive sessions. Engagement structured at an indicative commitment of 0.4–0.5 FTE (16–20 hours per week), enabling ongoing external consulting leadership subject to standard conflict-of-interest protocols.

Reporting structure

Reporting line: Indicative reporting to Chief Operating Officer / Chief Executive Officer; interfaces with Board Quality & Compliance Committee (Subject to Confirmation)

Department: Global Regulatory Affairs, Quality Assurance & Clinical Compliance

Application instructions

This opportunity is presented exclusively through Westbridge Search's executive-search and talent intelligence channel as a confidential executive-search mandate. It is not presented as a publicly advertised vacancy on the target company's corporate website or public recruitment portals. Westbridge Search acts as an independent executive-search intermediary identifying and evaluating senior leadership alignment for high-impact MedTech and diagnostics engagements. Any subsequent candidate engagement, formal representation, exploratory introduction, or submission process will be coordinated strictly through Westbridge Search in accordance with applicable professional arrangements and only where mutually agreed in writing. This document contains confidential executive-search information and is intended exclusively for the selected executive to whom it has been presented. The information is provided solely for the purpose of reviewing and evaluating the executive mandate described herein. This document, including its contents, analysis, responsibilities, commercial information, and associated materials, must not be copied, reproduced, distributed, forwarded, published, or disclosed to any third party without prior written authorisation from Westbridge Search. The recipient is requested to treat the contents with appropriate professional discretion and maintain the confidentiality of the information throughout any subsequent evaluation or discussion. Prepared for: Parul Chansoria.

Independent analysis

This is a confidential fractional executive mandate presented through Westbridge Search for Outset Medical, Inc. (NASDAQ: OM), a commercial-stage renal care technology company. The role carries significant strategic weight despite its fractional structure (0.4–0.5 FTE), reflecting a market trend toward accessing senior regulatory and quality expertise without full-time overhead. The compensation structure ($162K–$216K annualized retainer against a $385K–$440K FTE benchmark) represents approximately 42%–49% of full-time equivalent base, consistent with fractional executive market rates for Bay Area MedTech. The mandate's emphasis on FDA QMSR transition, SaMD/cybersecurity compliance, and international market expansion aligns with current regulatory pressures facing connected medical device manufacturers. The three-part specialised documentation requirement (regulatory strategy dossier, CAPA/inspection readiness architecture, Board risk dashboard) suggests a rigorous, multi-stage evaluation process designed to assess both technical depth and executive communication capability. The 90-180 day transition framework indicates expectations for rapid diagnostic assessment and measurable impact within the first two quarters. The role's dual reporting to COO/CEO with Board committee interface reflects the elevated governance profile of regulatory and quality functions in commercial-stage MedTech. This opportunity would suit an experienced RA/QA executive seeking portfolio-style advisory work with a publicly traded device manufacturer navigating the transition from acute care to home dialysis markets.

Interested in this role?

Westbridge reviews role enquiries and responds with relevant information about the opportunity and its application process.

Ask about this role →

More opportunities

Loading roles…